Carolina Reduzzi
@creduzzi.bsky.social
Reposted by Carolina Reduzzi
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
March 14, 2025 at 3:48 PM
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!
bit.ly/43JzN03
@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
Reposted by Carolina Reduzzi
#ISLB is conducting a global survey on the use of #LiquidBiopsy to uncover current and emerging challenges worldwide.
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy
About the survey
This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary.
The survey ...
docs.google.com
December 1, 2024 at 9:25 PM
#ISLB is conducting a global survey on the use of #LiquidBiopsy to uncover current and emerging challenges worldwide.
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
Reposted by Carolina Reduzzi
Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations.
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC
Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling
The study explored endocrine resistance by leveraging machine learning to establish the prognostic stratification of predicted Circulating tumor cells…
www.sciencedirect.com
November 23, 2024 at 7:20 PM
Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations.
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC